Ranolazine

An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.

Also Known As:

N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide; RS 43285; RS 43285-193; RS-43285; Ranexa; Ranolazine Dihydrochloride; Ranolazine HCl; Ranolazine Hydrochloride; Renolazine; 43285, RS; Dihydrochloride, Ranolazine; HCl, Ranolazine; Hydrochloride, Ranolazine; RS 43285 193; RS 43285193; RS43285

Networked: 598 relevant articles (109 outcomes, 179 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Belardinelli, Luiz: 74 articles (01/2021 - 08/2004)
2.	Morrow, David A: 24 articles (01/2021 - 06/2006)
3.	Scirica, Benjamin M: 24 articles (01/2021 - 06/2006)
4.	Braunwald, Eugene: 16 articles (01/2015 - 06/2006)
5.	Maier, Lars S: 13 articles (01/2018 - 10/2009)
6.	Antzelevitch, Charles: 13 articles (10/2016 - 08/2004)
7.	Murphy, Sabina A: 13 articles (08/2015 - 04/2007)
8.	Rajamani, Sridharan: 12 articles (10/2019 - 11/2009)
9.	Chaitman, Bernard R: 12 articles (10/2015 - 01/2004)
10.	Kloner, Robert A: 12 articles (10/2014 - 07/2006)

Related Diseases

1.	Stable Angina 10/01/2014 - "These data suggest that ranolazine is particularly beneficial in patients with stable angina who have suboptimally controlled T2DM." 08/01/2006 - "Ranolazine is a unique antianginal agent that has been effective in stable angina, but it has not been studied in the setting of maximum recommended doses of conventional antianginal agents. " 01/01/2018 - "Ranolazine, which is currently approved for chronic stable angina, has been shown to improve RV function in an animal model and has been shown to be safe in small human studies with PAH. " 07/01/2001 - "Ranolazine: a potential new treatment for chronic stable angina." 12/01/2007 - "Ranolazine: a new option in the management of chronic stable angina."
2.	Ischemia 04/27/2010 - "Ranolazine was associated with a significant reduction in recurrent ischemia in women (13.0% versus 18.2%; hazard ratio, 0.71; 95% confidence interval, 0.57 to 0.88; P=0.002). " 12/01/2006 - "One trial demonstrated that monotherapy with extended-release ranolazine was effective against angina and ischemia in patients with CSA. " 10/01/2018 - "Our data show that ranolazine, but not ISMN, improved time to ischemia during EST. " 12/01/2006 - "Ranolazine (9 microM) reduced d[Ca2+]i accumulation during ischemia as well as reperfusion and improved recovery of LV function. " 01/01/2019 - "The late Na+ current blocker ranolazine has shown to reduce the risk of recurrent ischemia and worsening of angina in patients with non-ST-segment elevation ACS by possibly improving myocardial perfusion, but up to now no trial has addressed whether this enhanced perfusion also leads to a decrease in ischemic myocardium of patients with ACS. "
3.	Atrial Fibrillation 09/01/2012 - "A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation. " 01/01/2014 - "Refractory atrial fibrillation effectively treated with ranolazine." 10/01/2014 - "Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications." 04/03/2010 - "Ranolazine, another atrial-selective agent initially developed as an antianginal, has efficacy for atrial fibrillation and is being tested in prospective clinical trials. " 06/01/2017 - "Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis."
4.	Myocardial Ischemia (Ischemic Heart Diseases) 11/15/2012 - "Ranolazine ameliorates myocardial ischemia by augmenting myocardial blood flow; likely by a reduction in the extravascular compression of small vessels. " 05/01/2011 - "We previously reported that ranolazine improved myocardial ischemia during exercise myocardial perfusion imaging (MPI). " 01/01/2019 - "A single-arm, open-label trial was conducted to quantify the impact of ranolazine on angina in women with ischemic heart disease (IHD). " 06/01/2017 - "Erratum to: Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)." 06/01/2017 - "Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)."
5.	Coronary Artery Disease (Coronary Atherosclerosis) 04/28/2009 - "In this largest study of ranolazine in patients with established coronary artery disease, ranolazine was effective in reducing angina with favorable safety in a substantially broader group of patients with angina than previously studied. " 01/01/2017 - "In an exploratory randomized controlled trial of symptomatic patients with CMD and no coronary artery disease, promising results were seem with ranolazine and CFR improving at 30 days. " 11/15/2012 - "Patients (n = 32) with known or suspected coronary artery disease and reversible perfusion defects on a clinically indicated stress myocardial perfusion imaging were restudied 4 weeks after ranolazine (500 to 1,000 mg orally twice daily) was added to their conventional treatment in an open-label trial (data previously reported). " 01/01/1990 - "This preliminary study suggests that ranolazine may significantly prolong exercise time in patients with stable coronary artery disease without altering heart rates and blood pressure." 08/01/2021 - "Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease."

Related Drugs and Biologics

1.	Sodium
2.	Neurofibromin 2 (Merlin)
3.	Dronedarone
4.	Trimetazidine (Vastarel)
5.	Adenosine Triphosphate (ATP)
6.	Sodium Channels (Sodium Channel)
7.	Nitroglycerin (Dynamite)
8.	Amiodarone (Amiodarona)
9.	Fatty Acids (Saturated Fatty Acids)
10.	Atenolol (Tenormin)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Electric Countershock (Cardioversion)
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Drug Therapy (Chemotherapy)